Pureos Bioventures, a Switzerland-based venture capital firm backed by undisclosed strategic investors in life sciences, has extended the size of its first fund to $205m.
The final closing of BB Pureos Bioventures will target a portfolio of 17 to 20 pre-clinical and clinical-stage companies in Europe developing novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies.
Its initial investments include Lava Therapeutics (floated on Nasdaq stock exchange in March), Alentis Therapeutics, AM-Pharma, Araris, Corlieve Therapeutics, Eyevensys, Imcheck Therapeutics, Lava Therapeutics, NovaGo Therapeutics, River Renal and Vico Therapeutics.
In addition, Pureos is a partner of BaseLaunch, a startup accelerator in Basel, Switzerland.
Klaus Breiner, Dominik Escher, Anja Harmeier, and Martin Münchbach are partners at Pureos.
